Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.

Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y, Zeng G, Wunderlich JR, Nguyen DM, Restifo NP, Schrump DS.

Cancer Res. 2006 Jan 15;66(2):1105-13.

2.

The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma.

Natsume A, Wakabayashi T, Tsujimura K, Shimato S, Ito M, Kuzushima K, Kondo Y, Sekido Y, Kawatsura H, Narita Y, Yoshida J.

Int J Cancer. 2008 Jun 1;122(11):2542-53. doi: 10.1002/ijc.23407.

3.

5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications.

Coral S, Sigalotti L, Altomonte M, Engelsberg A, Colizzi F, Cattarossi I, Maraskovsky E, Jager E, Seliger B, Maio M.

Clin Cancer Res. 2002 Aug;8(8):2690-5.

4.

Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.

Atanackovic D, Luetkens T, Kloth B, Fuchs G, Cao Y, Hildebrandt Y, Meyer S, Bartels K, Reinhard H, Lajmi N, Hegewisch-Becker S, Schilling G, Platzbecker U, Kobbe G, Schroeder T, Bokemeyer C, Kröger N.

Am J Hematol. 2011 Nov;86(11):918-22. doi: 10.1002/ajh.22141. Epub 2011 Sep 2.

5.

5-Aza-2'-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy.

Wachowska M, Gabrysiak M, Muchowicz A, Bednarek W, Barankiewicz J, Rygiel T, Boon L, Mroz P, Hamblin MR, Golab J.

Eur J Cancer. 2014 May;50(7):1370-81. doi: 10.1016/j.ejca.2014.01.017. Epub 2014 Feb 18.

6.

The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.

Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, Karbach J, Pfeifer D, Jäger E, Lübbert M.

Leuk Res. 2010 Jul;34(7):899-905. doi: 10.1016/j.leukres.2010.02.004. Epub 2010 Apr 10.

PMID:
20381863
7.

Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.

Yan M, Himoudi N, Basu BP, Wallace R, Poon E, Adams S, Hasan F, Xue SA, Wilson N, Dalgleish A, Williams O, Anderson J.

Cancer Immunol Immunother. 2011 Sep;60(9):1243-55. doi: 10.1007/s00262-011-1024-4. Epub 2011 May 7.

PMID:
21553146
8.

Identification of a meiosis-specific protein, MEIOB, as a novel cancer/testis antigen and its augmented expression in demethylated cancer cells.

Shiohama Y, Ohtake J, Ohkuri T, Noguchi D, Togashi Y, Kitamura H, Nishimura T.

Immunol Lett. 2014 Mar-Apr;158(1-2):175-82. doi: 10.1016/j.imlet.2014.01.004. Epub 2014 Jan 16.

PMID:
24440806
9.

Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.

Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F, Fonsatti E, Traversari C, Altomonte M, Maio M.

Cancer Res. 2004 Dec 15;64(24):9167-71.

10.

Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications.

Coral S, Sigalotti L, Colizzi F, Spessotto A, Nardi G, Cortini E, Pezzani L, Fratta E, Fonsatti E, Di Giacomo AM, Nicotra MR, Natali PG, Altomonte M, Maio M.

J Cell Physiol. 2006 Apr;207(1):58-66.

PMID:
16252259
11.
12.

Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma.

Li B, Zhu X, Sun L, Yuan L, Zhang J, Li H, Ye Z.

Oncotarget. 2014 Nov 15;5(21):10791-802.

13.

Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules.

Adair SJ, Hogan KT.

Cancer Immunol Immunother. 2009 Apr;58(4):589-601. doi: 10.1007/s00262-008-0582-6. Epub 2008 Sep 13.

PMID:
18791715
14.

Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.

Reu FJ, Bae SI, Cherkassky L, Leaman DW, Lindner D, Beaulieu N, MacLeod AR, Borden EC.

J Clin Oncol. 2006 Aug 10;24(23):3771-9. Epub 2006 Jun 26.

PMID:
16801630
15.

Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer.

Chou J, Voong LN, Mortales CL, Towlerton AM, Pollack SM, Chen X, Yee C, Robbins PF, Warren EH.

J Immunother. 2012 Feb-Mar;35(2):131-41. doi: 10.1097/CJI.0b013e31824300c7.

16.
17.

Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer.

Rao M, Chinnasamy N, Hong JA, Zhang Y, Zhang M, Xi S, Liu F, Marquez VE, Morgan RA, Schrump DS.

Cancer Res. 2011 Jun 15;71(12):4192-204. doi: 10.1158/0008-5472.CAN-10-2442. Epub 2011 May 5.

18.

DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer.

Terracina KP, Graham LJ, Payne KK, Manjili MH, Baek A, Damle SR, Bear HD.

Cancer Immunol Immunother. 2016 Sep;65(9):1061-73. doi: 10.1007/s00262-016-1868-8. Epub 2016 Jul 14.

19.

Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide.

Coral S, Parisi G, Nicolay HJ, Colizzi F, Danielli R, Fratta E, Covre A, Taverna P, Sigalotti L, Maio M.

Cancer Immunol Immunother. 2013 Mar;62(3):605-14. doi: 10.1007/s00262-012-1365-7. Epub 2012 Nov 9.

PMID:
23138873
20.

Demethylating agent decitabine induces autologous cancer testis antigen specific cytotoxic T lymphocytes in vivo.

Zhou JH, Yao YS, Wang LX, Wang J, Li YH, Jiang MM, Zhou MH, Gao XN, Li RS, Wang LL, Yu L.

Chin Med J (Engl). 2013 Dec;126(23):4552-6.

PMID:
24286424

Supplemental Content

Support Center